3
Announcements
Trials
Browse
Landscape
Status
Recruiting
59
Active not recruiting
25
Completed
19
Not yet recruiting
11
Terminated
6
Enrolling by invitation
3
Withdrawn
2
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
3
Melanoma
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Ovarian Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Ductal Adenocarcinoma (PDAC)
1
Osteosarcoma
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neuroblastoma
1
Myelodysplastic Syndromes
1
Meningioma
1
Mastocytosis, Systemic
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Interventions
tisagenlecleucel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
Leukemia
×
90 days
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available